Cadila, Recipharm get nod for foreign equity investment

New Delhi, Jan 14 (IANS) A proposal from drugmaker Cadila to inject foreign equity of Rs.5,000 crore towards expansion in India is among the five proposals approved by the Foreign Investment Promotion Board (FIPB) in its latest meeting, an official statement said on Thursday.

Another proposal, again from a global pharmaceuticals company, that was approved is from Sweden-based Recipharm Participation for incorporating a subsidiary in India with an investment of Rs.1,050 crore for investing in other companies, the statement added.

In October last year, Recipharm had announced that it was entering into an agreement to acquire 74 percent majority stake in Nitin Lifesciences, an Indian contract manufacturing firm in the sterile injectables business, for Rs.671 crore.

Almost all the other proposals in areas ranging from financial services to cement did not involve any foreign equity infusion.

Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of www.mangalorean.com or any employee thereof. www.mangalorean.com is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of www.mangalorean.com to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at  info@mangalorean.com. Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here